Drug Trial Radar · NCT06532253
Long-term Safety Trial with NVDX3
Last checked: Nov 19, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Aug 22, 2024
Primary completion
Mar 2036
Study completion Mar 2036
Sponsor
- Lead sponsor
- Novadip BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- PrimeVigilance; Data Investigation Company Europe (DICE)
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An study evaluating the long-term safety of all patients previously treated with NVDX3.
Conditions
- Distal Radius Fractures
- Degenerative Lumbar Spondylolisthesis
Interventions
NVDX3Drug
NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety of the NVDX3 implantTime frame: Between screening (V0) and 120 months post-core study (V10)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.